Enforcement Of Second Medical Use Patents: Landmark Case Sets The Scene For Future Battles

Mike Snodin discusses the UK Court of Appeal’s recent decision on second medical use patents and “skinny label” generic products that, whilst containing encouraging signs for the innovative pharmaceutical industry, leaves open key questions that can only be answered in further disputes.